<DOC>
	<DOCNO>NCT01765543</DOCNO>
	<brief_summary>This open-label , multi-center , three-period , one-sequence study investigate effect rifampin PK vemurafenib participant unresectable BRAFV600-mutation positive metastatic melanoma malignant tumor type harbor V600-activating mutation BRAF without acceptable standard treatment option . Eligible participant option continue treatment vemurafenib part extension study GO28399 ( NCT01739764 ) .</brief_summary>
	<brief_title>A Pharmacokinetics ( PK ) Study Investigate Effect Rifampin PK Vemurafenib ( Zelboraf )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Participants either unresectable Stage IIIc Stage IV metastatic melanoma positive BRAF V600 mutation malignant tumor type harbor V600activating mutation BRAF , determine result cobasÂ® 4800 BRAF V600 mutation test Deoxyribonucleic acid ( DNA ) sequence method , acceptable standard treatment option Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy great equal ( &gt; /= ) 12 week Full recovery effect major surgery significant traumatic injury within 14 day prior first dose study treatment Adequate hematologic end organ function Female participant childbearing potential male participant partner childbearing potential must agree always use 2 effective method contraception Negative serum pregnancy test within 7 day prior commencement dose woman childbearing potential Prior treatment vemurafenib BRAF inhibitor within 42 day first dose study drug Requirement immediate urgent treatment daily vemurafenib intermittent schedule vemurafenib employed 24day period trial clinically acceptable Allergy hypersensitivity component vemurafenib formulation Experimental therapy within 4 week prior first dose study drug Major surgical procedure significant traumatic injury within 14 day prior first dose study drug , anticipation need major surgery study treatment Prior anticancer therapy within 28 day first dose study drug History clinically significant cardiac pulmonary dysfunction History symptomatic congestive heart failure New York Heart Association class serious cardiac arrhythmia require treatment History myocardial infarction within 6 month prior first dose study drug Current dyspnea rest , owe complication advance malignancy requirement supplemental oxygen perform activity daily live History congenital long QT syndrome correct QT interval ( QTc ) great ( &gt; ) 450 millisecond Active central nervous system lesion Uncontrolled poorly control diabetes Current severe , uncontrolled systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>